A detailed history of Sectoral Asset Management Inc transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Sectoral Asset Management Inc holds 2,141 shares of ASND stock, worth $291,989. This represents 0.27% of its overall portfolio holdings.

Number of Shares
2,141
Previous 2,666 19.69%
Holding current value
$291,989
Previous $363,000 12.12%
% of portfolio
0.27%
Previous 0.18%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$113.0 - $153.43 $59,325 - $80,550
-525 Reduced 19.69%
2,141 $319,000
Q2 2024

Aug 13, 2024

SELL
$121.07 - $153.67 $162,839 - $206,686
-1,345 Reduced 33.53%
2,666 $363,000
Q1 2024

May 14, 2024

SELL
$123.45 - $159.4 $53,083 - $68,542
-430 Reduced 9.68%
4,011 $606,000
Q4 2023

Feb 14, 2024

BUY
$86.1 - $127.36 $17,220 - $25,472
200 Added 4.72%
4,441 $559,000
Q3 2023

Nov 14, 2023

BUY
$86.5 - $103.97 $124,992 - $150,236
1,445 Added 51.68%
4,241 $397,000
Q2 2023

Aug 11, 2023

BUY
$69.96 - $97.84 $77,375 - $108,211
1,106 Added 65.44%
2,796 $249,000
Q4 2022

Feb 10, 2023

SELL
$99.42 - $131.97 $19,884 - $26,394
-200 Reduced 10.58%
1,690 $206,000
Q2 2022

Aug 15, 2022

SELL
$78.08 - $117.61 $330,981 - $498,548
-4,239 Reduced 69.16%
1,890 $176,000
Q4 2021

Feb 11, 2022

SELL
$127.1 - $169.66 $4.13 Million - $5.52 Million
-32,521 Reduced 84.14%
6,129 $825,000
Q3 2021

Nov 15, 2021

BUY
$112.67 - $176.92 $3.95 Million - $6.21 Million
35,100 Added 988.73%
38,650 $6.16 Million
Q2 2021

Aug 16, 2021

BUY
$121.62 - $145.29 $36,486 - $43,587
300 Added 9.23%
3,550 $467,000
Q1 2021

May 14, 2021

BUY
$124.92 - $173.33 $405,990 - $563,322
3,250 New
3,250 $419,000

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.61B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Sectoral Asset Management Inc Portfolio

Follow Sectoral Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sectoral Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Sectoral Asset Management Inc with notifications on news.